Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger

Kimberly-Clark has announced its intention to acquire Kenvue, the company behind Tylenol, in a significant $40 billion merger. This move comes at a time when Kenvue is facing lawsuits and regulatory challenges, making the acquisition particularly noteworthy. The deal highlights Kimberly-Clark's strategy to expand its portfolio in the consumer health sector, especially as Kenvue navigates through troubled waters. This merger could reshape the landscape of consumer health products, impacting both companies and their consumers.